ClinicalTrials.gg
WithdrawnNCT05372887Updated Dec 11, 2023

Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

A Phase 2 interventional study of TNX-102 SL and Placebo in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Withdrawn at 3 sites in Kenya. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The study was stopped due to business reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)-a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible patients will have a telephonic visit at week 2 and then return regularly to the study clinic for monthly visits for assessments of efficacy and safety.

02

Conditions studied

03

In context

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 75 years of age, at the time of signing ICF, inclusive.
  • Diagnosed with current (past month) PTSD as determined by the MINI 7.0.2 Module H (PTSD).
  • Index trauma(s) resulting in PTSD must meet Criterion A for PTSD as described in the CAPS 5, must have occurred within 9 years of Screening Visit 1, and must have occurred when the participant was ≥18 years of age.
  • Willing and able to withdraw and refrain from opioids for the course of the study.
  • Willing to refrain from use of all other formulations of cyclobenzaprine for the course of the study.
  • Willing and able to refrain from antidepressants and other excluded medications.
  • Capable of reading and understanding English and able to provide written to participate.
  • Willing to comply with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  • If female, either not of or practicing a medically acceptable method of throughout the study.
  • (BMI) within the range 17.5 - 35 kg/m\^2 (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Current or ongoing exposure to the trauma that resulted in the PTSD (ie, non-work-related trauma such as ongoing domestic abuse).
  • Increased risk of suicide, based on the investigator's judgment that is of a severity that is not appropriate for outpatient management, or that warrants additional therapy excluded by the protocol.
  • Significant (eg, moderate or severe) comorbid traumatic brain injury (TBI) by history.
  • Severe depressive symptoms at screening or baseline.
  • laboratory abnormalities based on screening laboratory tests and/or medical history in the investigator's opinion.
  • Use of antidepressant medication within 2 months of baseline.
  • Female participants who are pregnant or lactating.
  • History of serotonin syndrome, severe allergic reaction or bronchospasm or known to cyclobenzaprine or the in TNX-102 SL or placebo formulations.
  • Seizure disorder.
  • Current moderate or severe sleep apnea not well controlled by positive airway pressure (PAP) or oral (mouthpiece) devices.
  • Has received any other drug within 90 days before Screening or has taken cyclobenzaprine within 21 days of the Randomization visit.
  • Previous participation in any other study with TNX-102 SL.
  • Family member of investigative staff.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TNX-102 SL, 5.6 mg

    2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.

    Drug: TNX-102 SL

  • Placebo comparator
    Placebo

    2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.

    Drug: Placebo

Interventions

  • Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks

    Also known as: Low dose cyclobenzaprine sublingual tablets

  • DrugPlacebo

    Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks

    Also known as: Placebo sublingual tablets

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in the total Clinician Administered PTSD Scale (CAPS-5) for DSM-5 at Week 12.

    To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the Clinician Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (CAPS-5) total symptom severity score in a 12-week study.

    Time frame: Day 1, Week 4, Week 12

Secondary outcomes

  1. Clinical Global Impression - Severity change from Baseline to Week 12

    CGI-S to assess global severity change from baseline to Week 12

    Time frame: Day 1, Week 4, Week 8, Week 12

  2. Change from baseline in the disruption of psychosocial functioning assessed using the Sheehan Disability Scale (SDS) after 12 weeks of treatment.

    SDS to assess psychosocial functioning change from baseline to Week 12

    Time frame: Day 1, Week 4, Week 8, Week 12

07

Study locations

3 sites
  • Aga Khan University Clinical Research Unit
    Nairobi, Kenya
  • Centre for Clinical Research at KEMRI-Nairobi
    Nairobi, Kenya
  • Moi University Clinical Research Centre
    Nairobi, Kenya
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Nov 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 13, 2022
StartActual
Oct 14, 2022
Primary completionActual
Nov 8, 2022
CompletionActual
Nov 8, 2022
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05372887
Responsible party
Sponsor
First posted
May 13, 2022
Start date
Oct 14, 2022
Primary completion
Nov 8, 2022
Completion
Nov 8, 2022
Last update
Dec 11, 2023

Study contacts

Gregory Sullivan, MD
study director · Tonix Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion